|
US7214660B2
(en)
*
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
|
US8008252B2
(en)
*
|
2001-10-10 |
2011-08-30 |
Novo Nordisk A/S |
Factor VII: remodeling and glycoconjugation of Factor VII
|
|
US7173003B2
(en)
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
|
US7157277B2
(en)
|
2001-11-28 |
2007-01-02 |
Neose Technologies, Inc. |
Factor VIII remodeling and glycoconjugation of Factor VIII
|
|
WO2003062290A1
(en)
|
2002-01-16 |
2003-07-31 |
Biocompatibles Uk Limited |
Polymer conjugates
|
|
MXPA04012496A
(es)
*
|
2002-06-21 |
2005-09-12 |
Novo Nordisk Healthcare Ag |
Glicoformos del factor vii pegilados.
|
|
GB0301014D0
(en)
*
|
2003-01-16 |
2003-02-19 |
Biocompatibles Ltd |
Conjugation reactions
|
|
CA2788505C
(en)
|
2003-02-26 |
2018-09-04 |
Nektar Therapeutics |
Polymer-factor viii moiety conjugates
|
|
US8791070B2
(en)
|
2003-04-09 |
2014-07-29 |
Novo Nordisk A/S |
Glycopegylated factor IX
|
|
WO2006127896A2
(en)
|
2005-05-25 |
2006-11-30 |
Neose Technologies, Inc. |
Glycopegylated factor ix
|
|
EP1615945B1
(en)
|
2003-04-09 |
2011-09-28 |
BioGeneriX AG |
Glycopegylation methods and proteins/peptides produced by the methods
|
|
US7887789B2
(en)
*
|
2003-05-23 |
2011-02-15 |
Nektar Therapeutics |
Polymer derivatives having particular atom arrangements
|
|
US7947261B2
(en)
|
2003-05-23 |
2011-05-24 |
Nektar Therapeutics |
Conjugates formed from polymer derivatives having particular atom arrangements
|
|
WO2005012484A2
(en)
|
2003-07-25 |
2005-02-10 |
Neose Technologies, Inc. |
Antibody-toxin conjugates
|
|
WO2005039641A2
(en)
*
|
2003-10-15 |
2005-05-06 |
The Regents Of The University Of California |
Biomacromolecule polymer conjugates
|
|
US20080305992A1
(en)
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
|
US20060040856A1
(en)
|
2003-12-03 |
2006-02-23 |
Neose Technologies, Inc. |
Glycopegylated factor IX
|
|
US6887952B1
(en)
*
|
2004-02-12 |
2005-05-03 |
Biosite, Inc. |
N-aryl-carbamic acid ester-derived and valeric acid ester-derived cross-linkers and conjugates, and methods for their synthesis and use
|
|
JP4805911B2
(ja)
*
|
2004-03-15 |
2011-11-02 |
ネクター セラピューティクス |
Ｈｉｖ侵入阻害剤のポリマー系組成物及び複合体
|
|
US8470315B2
(en)
|
2004-04-13 |
2013-06-25 |
Quintessence Biosciences, Inc. |
Non-natural ribonuclease conjugates as cytotoxic agents
|
|
WO2006010143A2
(en)
|
2004-07-13 |
2006-01-26 |
Neose Technologies, Inc. |
Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
|
|
EP1814573B1
(en)
|
2004-10-29 |
2016-03-09 |
ratiopharm GmbH |
Remodeling and glycopegylation of fibroblast growth factor (fgf)
|
|
AU2013203348B2
(en)
*
|
2004-11-12 |
2016-03-03 |
Bayer Healthcare Llc |
Site-directed modification of FVIII
|
|
AU2016203693B2
(en)
*
|
2004-11-12 |
2018-08-23 |
Bayer Healthcare Llc |
Site-directed modification of FVIII
|
|
US7632921B2
(en)
|
2004-11-12 |
2009-12-15 |
Bayer Healthcare Llc |
Site-directed modification of FVIII
|
|
AU2012203813B2
(en)
*
|
2004-11-12 |
2013-10-24 |
Bayer Healthcare Llc |
Site-directed modification of FVIII
|
|
DK1835938T3
(da)
|
2004-12-27 |
2013-11-04 |
Baxter Int |
Polymer-von Willebrand-faktor-konjugater
|
|
CA2593682C
(en)
|
2005-01-10 |
2016-03-22 |
Neose Technologies, Inc. |
Glycopegylated granulocyte colony stimulating factor
|
|
WO2006089228A2
(en)
*
|
2005-02-16 |
2006-08-24 |
Nektar Therapeutics Al, Corporation |
Conjugates of an epo moiety and a polymer
|
|
EP1861125A2
(en)
*
|
2005-03-23 |
2007-12-05 |
Nektar Therapeutics Al, Corporation |
Conjugates of an hgh moiety and peg derivatives
|
|
WO2006103298A2
(en)
*
|
2005-04-01 |
2006-10-05 |
Novo Nordisk Health Care Ag |
Blood coagulation fviii analogues
|
|
EP1871795A4
(en)
*
|
2005-04-08 |
2010-03-31 |
Biogenerix Ag |
COMPOSITIONS AND METHOD FOR PRODUCING GLYCOSYLATION MUTANTS OF A PROTEASE-RESISTANT HUMAN GROWTH HORMONE
|
|
EP1885403B1
(en)
|
2005-04-12 |
2013-05-08 |
Nektar Therapeutics |
Poly(ethyleneglycol) conjugates of Lysostaphin
|
|
JP5335422B2
(ja)
*
|
2005-06-17 |
2013-11-06 |
ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト |
少なくとも１つの非天然のシステインを含んでいる操作されたタンパク質の選択的な還元および誘導体化
|
|
WO2007019331A2
(en)
*
|
2005-08-04 |
2007-02-15 |
Nektar Therapeutics Al, Corporation |
Conjugates of a g-csf moiety and a polymer
|
|
US20070105755A1
(en)
*
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
|
WO2007056191A2
(en)
|
2005-11-03 |
2007-05-18 |
Neose Technologies, Inc. |
Nucleotide sugar purification using membranes
|
|
WO2007078820A2
(en)
*
|
2005-12-19 |
2007-07-12 |
Sun Bio, Inc. |
Methylmaleimidyl polymer derivatives
|
|
KR101434612B1
(ko)
*
|
2006-03-30 |
2014-08-26 |
팔라틴 테크놀로지스 인코포레이티드 |
사이클릭 나트륨 이뇨 펩타이드 구조물
|
|
US7795221B2
(en)
*
|
2006-03-30 |
2010-09-14 |
Palatin Technologies, Inc. |
Linear natriuretic peptide constructs
|
|
US8580746B2
(en)
*
|
2006-03-30 |
2013-11-12 |
Palatin Technologies, Inc. |
Amide linkage cyclic natriuretic peptide constructs
|
|
US7982010B2
(en)
*
|
2006-03-31 |
2011-07-19 |
Baxter International Inc. |
Factor VIII polymer conjugates
|
|
US7985839B2
(en)
*
|
2006-03-31 |
2011-07-26 |
Baxter International Inc. |
Factor VIII polymer conjugates
|
|
EP2010222A1
(en)
*
|
2006-03-31 |
2009-01-07 |
Baxter International Inc. |
Pegylated factor viii
|
|
US7645860B2
(en)
*
|
2006-03-31 |
2010-01-12 |
Baxter Healthcare S.A. |
Factor VIII polymer conjugates
|
|
KR20090013816A
(ko)
*
|
2006-05-24 |
2009-02-05 |
노보 노르디스크 헬스 케어 악티엔게젤샤프트 |
연장된 생체내 반감기를 갖는 인자 ⅸ 유사체
|
|
EP2044097A4
(en)
|
2006-06-23 |
2010-10-06 |
Quintessence Biosciences Inc |
Modified ribonucleases
|
|
US8298801B2
(en)
*
|
2006-07-17 |
2012-10-30 |
Quintessence Biosciences, Inc. |
Methods and compositions for the treatment of cancer
|
|
US9187532B2
(en)
|
2006-07-21 |
2015-11-17 |
Novo Nordisk A/S |
Glycosylation of peptides via O-linked glycosylation sequences
|
|
US20100075375A1
(en)
*
|
2006-10-03 |
2010-03-25 |
Novo Nordisk A/S |
Methods for the purification of polypeptide conjugates
|
|
PT2101821E
(pt)
*
|
2006-12-15 |
2014-10-03 |
Baxter Int |
Fator conjugado viia-ácido (poli)siálico com prolongamento do tempo de meia vida in vivo
|
|
MX2009007146A
(es)
*
|
2006-12-27 |
2009-07-09 |
Nektar Therapeutics Al Corp |
Conjugados porcion del factor ix-polimero que tienen ligadura que se puede liberar.
|
|
US8133865B2
(en)
|
2006-12-27 |
2012-03-13 |
Nektar Therapeutics |
von Willebrand factor- and factor VIII-polymer conjugates having a releasable linkage
|
|
CN101796063B
(zh)
|
2007-04-03 |
2017-03-22 |
拉蒂奥法姆有限责任公司 |
使用糖聚乙二醇化g‑csf的治疗方法
|
|
WO2008154639A2
(en)
|
2007-06-12 |
2008-12-18 |
Neose Technologies, Inc. |
Improved process for the production of nucleotide sugars
|
|
WO2009045539A2
(en)
*
|
2007-10-05 |
2009-04-09 |
Nektar Therapeutics Al, Corporation |
Oligomer-corticosteroid conjugates
|
|
JP2010540681A
(ja)
|
2007-10-08 |
2010-12-24 |
クインテッセンス バイオサイエンシズ，インコーポレーテッド |
リボヌクレアーゼに基づく治療のための組成物及び方法
|
|
AU2008323768A1
(en)
*
|
2007-11-09 |
2009-05-14 |
Baxter Healthcare S.A. |
Modified recombinant Factor VIII and von Willebrand Factor and methods of use
|
|
CA2710518C
(en)
*
|
2007-12-27 |
2018-07-17 |
Baxter International Inc. |
Method and compositions for specifically detecting physiologically acceptable polymer molecules
|
|
CN103497247A
(zh)
|
2008-02-27 |
2014-01-08 |
诺沃—诺迪斯克有限公司 |
缀合的因子viii分子
|
|
TWI395593B
(zh)
|
2008-03-06 |
2013-05-11 |
Halozyme Inc |
可活化的基質降解酵素之活體內暫時性控制
|
|
NZ601248A
(en)
|
2008-04-14 |
2014-06-27 |
Halozyme Inc |
Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
|
|
TWI394580B
(zh)
|
2008-04-28 |
2013-05-01 |
Halozyme Inc |
超快起作用胰島素組成物
|
|
BRPI0913374A2
(pt)
|
2008-06-04 |
2015-11-24 |
Bayer Healthcare Llc |
muteínas fviii para tratamento de doença de von willebrand
|
|
DK2865760T3
(en)
|
2008-06-24 |
2018-01-15 |
Csl Behring Gmbh |
Factor VIII, Von Willebrand Factor or complexes thereof with extended in vivo half-life
|
|
WO2010014258A2
(en)
*
|
2008-08-01 |
2010-02-04 |
Nektar Therapeutics Al, Corporation |
Conjugates having a releasable linkage
|
|
AU2009282747B2
(en)
*
|
2008-08-22 |
2015-04-02 |
Takeda Pharmaceutical Company Limited |
Polymeric benzyl carbonate-derivatives
|
|
US8029782B2
(en)
|
2008-10-01 |
2011-10-04 |
Quintessence Biosciences, Inc. |
Therapeutic ribonucleases
|
|
US8143347B2
(en)
|
2008-10-15 |
2012-03-27 |
Baxter International Inc. |
Pegylation of recombinant blood coagulation factors in the presence of bound antibodies
|
|
PT2349342T
(pt)
*
|
2008-10-17 |
2018-10-26 |
Baxalta Inc |
Factores sanguíneos modificados que compreendem um baixo grau de polímero solúvel na água
|
|
JP5281358B2
(ja)
*
|
2008-10-27 |
2013-09-04 |
学校法人常翔学園 |
高分子、経上皮吸収促進剤、及び医薬用製剤
|
|
KR20110093775A
(ko)
*
|
2008-11-03 |
2011-08-18 |
바이엘 헬스케어 엘엘씨 |
혈우병 치료 방법
|
|
EA036569B1
(ru)
|
2008-12-09 |
2020-11-24 |
Галозим, Инк. |
Способ получения полипептида гиалуронидазы ph20
|
|
WO2010083536A1
(en)
*
|
2009-01-19 |
2010-07-22 |
Bayer Healthcare Llc |
Protein conjugate having an endopeptidase-cleavable bioprotective moiety
|
|
US20110046060A1
(en)
|
2009-08-24 |
2011-02-24 |
Amunix Operating, Inc., |
Coagulation factor IX compositions and methods of making and using same
|
|
SI2393828T1
(sl)
|
2009-02-03 |
2017-01-31 |
Amunix Operating Inc. |
Podaljšani rekombinantni polipetidi in sestavki, ki jih obsegajo
|
|
JP2012518029A
(ja)
*
|
2009-02-19 |
2012-08-09 |
ノヴォ・ノルディスク・アー／エス |
第ｖｉｉｉ因子の修飾
|
|
US20120134977A1
(en)
|
2009-06-01 |
2012-05-31 |
Yeda Research And Development Co. Ltd. |
Prodrugs containing albumin binding probe
|
|
SG178051A1
(en)
|
2009-07-27 |
2012-03-29 |
Lipoxen Technologies Ltd |
Glycopolysialylation of non-blood coagulation proteins
|
|
SG178141A1
(en)
|
2009-07-27 |
2012-03-29 |
Baxter Int |
Blood coagulation protein conjugates
|
|
US8809501B2
(en)
|
2009-07-27 |
2014-08-19 |
Baxter International Inc. |
Nucleophilic catalysts for oxime linkage
|
|
CN104530182A
(zh)
|
2009-07-27 |
2015-04-22 |
利普森技术有限公司 |
非凝血蛋白的糖基多唾液酸化
|
|
US8642737B2
(en)
|
2010-07-26 |
2014-02-04 |
Baxter International Inc. |
Nucleophilic catalysts for oxime linkage
|
|
HRP20160530T1
(hr)
|
2009-09-17 |
2016-07-29 |
Baxalta Incorporated |
Stabilna ko-formulacija hijaluronidaze i imunoglobulina, te postupci njezine uporabe
|
|
WO2011131720A1
(en)
*
|
2010-04-20 |
2011-10-27 |
Octapharma Ag |
New stabilizing agent for pharmaceutical proteins
|
|
GB201007357D0
(en)
*
|
2010-04-30 |
2010-06-16 |
Leverton Licence Holdings Ltd |
Conjugated factor VIII
|
|
GB201007356D0
(en)
|
2010-04-30 |
2010-06-16 |
Leverton Licence Holdings Ltd |
Conjugated factor VIIa
|
|
US9611310B2
(en)
|
2010-07-09 |
2017-04-04 |
Bioverativ Therapeutics Inc. |
Systems for factor VIII processing and methods thereof
|
|
EP2595624B1
(en)
|
2010-07-20 |
2018-01-31 |
Halozyme, Inc. |
Methods of treatment or prevention of the adverse side-effects associated with administration of an anti-hyaluronan agent
|
|
TWI595004B
(zh)
|
2010-11-03 |
2017-08-11 |
介控生化科技公司 |
經修飾之第九因子多胜肽及其用途
|
|
DK2654794T3
(da)
|
2010-12-22 |
2020-06-08 |
Baxalta GmbH |
Materialer og fremgangsmåder til konjugering af et vandopløseligt fedtsyrederivat til et protein
|
|
JP2014510045A
(ja)
|
2011-02-08 |
2014-04-24 |
ハロザイム インコーポレイテッド |
ヒアルロナン分解酵素の組成物および脂質製剤ならびに良性前立腺肥大症の治療のためのその使用
|
|
EP2696897A2
(en)
|
2011-04-11 |
2014-02-19 |
Yeda Research and Development Co. Ltd. |
Albumin binding probes and drug conjugates thereof
|
|
WO2012140650A2
(en)
*
|
2011-04-12 |
2012-10-18 |
Hepacore Ltd. |
Conjugates of carboxy polysaccharides with fibroblast growth factors and variants thereof
|
|
CN105797140B
(zh)
|
2011-06-17 |
2020-08-11 |
哈洛齐梅公司 |
乙酰透明质酸降解酶的稳定制剂
|
|
US20130011378A1
(en)
|
2011-06-17 |
2013-01-10 |
Tzung-Horng Yang |
Stable formulations of a hyaluronan-degrading enzyme
|
|
BR112013032265A2
(pt)
|
2011-06-17 |
2016-12-20 |
Halozyme Inc |
métodos de infusão de insulina subcutânea contínua com uma enzima de degradação do hialuronano
|
|
WO2013040501A1
(en)
|
2011-09-16 |
2013-03-21 |
Pharmathene, Inc. |
Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and uses thereof
|
|
KR101828828B1
(ko)
|
2011-10-24 |
2018-03-29 |
할로자임, 아이엔씨 |
항-히알루로난 제제 치료를 위한 동반 진단 및 이의 사용 방법
|
|
BR112014016195A2
(pt)
|
2011-12-30 |
2020-10-27 |
Halozyme, Inc. |
variantes de polipeptídio ph20, formulações e usos das mesmas
|
|
CN111499761A
(zh)
*
|
2012-01-12 |
2020-08-07 |
比奥贝拉蒂治疗公司 |
嵌合因子viii多肽及其用途
|
|
NZ628014A
(en)
|
2012-02-15 |
2016-09-30 |
Biogen Ma Inc |
Recombinant factor viii proteins
|
|
CN111548418A
(zh)
|
2012-02-15 |
2020-08-18 |
比奥贝拉蒂治疗公司 |
因子viii组合物及其制备和使用方法
|
|
PL2814502T3
(pl)
|
2012-02-15 |
2018-02-28 |
Csl Behring Gmbh |
Warianty czynnika von Willebranda mające ulepszone powinowactwo do wiązania czynnika VIII
|
|
US9913822B2
(en)
|
2012-04-04 |
2018-03-13 |
Halozyme, Inc. |
Combination therapy with an anti-hyaluronan agent and therapeutic agent
|
|
EP2838566A2
(en)
*
|
2012-04-16 |
2015-02-25 |
Cantab Biopharmaceuticals Patents Limited |
Optimised subcutaneous therapeutic agents
|
|
US10202595B2
(en)
|
2012-06-08 |
2019-02-12 |
Bioverativ Therapeutics Inc. |
Chimeric clotting factors
|
|
EP2858659B1
(en)
|
2012-06-08 |
2019-12-25 |
Bioverativ Therapeutics Inc. |
Procoagulant compounds
|
|
US20140017265A1
(en)
*
|
2012-07-05 |
2014-01-16 |
Mersana Therapeutics, Inc. |
Terminally Modified Polymers and Conjugates Thereof
|
|
AU2013290173B2
(en)
|
2012-07-11 |
2018-02-15 |
Bioverativ Therapeutics Inc. |
Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof
|
|
US20160000884A1
(en)
*
|
2012-08-13 |
2016-01-07 |
Novo Nordisk A/S |
Liquid Factor VIII Formulations
|
|
WO2014062856A1
(en)
|
2012-10-16 |
2014-04-24 |
Halozyme, Inc. |
Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
|
|
EP2908847B1
(en)
|
2012-10-18 |
2022-03-30 |
Bioverativ Therapeutics Inc. |
Methods of using a fixed dose of a clotting factor
|
|
PT2966083T
(pt)
|
2013-03-05 |
2019-09-17 |
Hanmi Pharm Ind Co Ltd |
Método de preparação melhorado para produção de alto rendimento de conjugado de polipéptido fisiologicamente ativo
|
|
WO2014160272A1
(en)
*
|
2013-03-13 |
2014-10-02 |
Emory University |
Targeted elimination of factor viii immune cells
|
|
EA037906B1
(ru)
|
2013-03-15 |
2021-06-04 |
Биовератив Терапьютикс Инк. |
Препараты полипептида фактора ix
|
|
US20200157159A1
(en)
|
2013-04-16 |
2020-05-21 |
The Board Of Regents Of The University Of Oklahoma |
Peptide compounds and compositions thereof
|
|
ES2657291T3
(es)
|
2013-04-22 |
2018-03-02 |
Csl Ltd. |
Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
|
|
HK1223302A1
(zh)
|
2013-06-28 |
2017-07-28 |
Bioverativ Therapeutics Inc. |
具有xten的凝血酶可裂解连接子和其用途
|
|
TW201534726A
(zh)
|
2013-07-03 |
2015-09-16 |
Halozyme Inc |
熱穩定ｐｈ２０玻尿酸酶變異體及其用途
|
|
WO2015023894A1
(en)
|
2013-08-14 |
2015-02-19 |
Biogen Idec Ma Inc. |
Recombinant factor viii proteins
|
|
US10548953B2
(en)
|
2013-08-14 |
2020-02-04 |
Bioverativ Therapeutics Inc. |
Factor VIII-XTEN fusions and uses thereof
|
|
PH12016501323B1
(en)
|
2014-01-10 |
2022-04-29 |
Bioverativ Therapeutics Inc |
Factor viii chimeric proteins and uses thereof
|
|
EP3114138B1
(en)
|
2014-03-05 |
2021-11-17 |
Pfizer Inc. |
Improved muteins of clotting factor viii
|
|
EP3164150B1
(en)
|
2014-07-02 |
2020-11-04 |
CSL Behring Lengnau AG |
Modified von willebrand factor
|
|
HUE043847T2
(hu)
|
2014-08-28 |
2019-09-30 |
Halozyme Inc |
Hialuronán-lebontó enzimmel és egy immun checkpoint inhibitorral végzett kombinációs terápia
|
|
CN108064282A
(zh)
|
2014-10-14 |
2018-05-22 |
哈洛齐梅公司 |
腺苷脱氨酶-2(ada2)、其变体的组合物及使用其的方法
|
|
MA40835A
(fr)
|
2014-10-23 |
2017-08-29 |
Biogen Ma Inc |
Anticorps anti-gpiib/iiia et leurs utilisations
|
|
MA40861A
(fr)
|
2014-10-31 |
2017-09-05 |
Biogen Ma Inc |
Anticorps anti-glycoprotéines iib/iiia
|
|
KR20170125941A
(ko)
|
2015-03-06 |
2017-11-15 |
체에스엘 베링 리컴비넌트 퍼실리티 아게 |
개선된 반감기를 갖는 변형된 폰 빌레브란트 인자
|
|
EP4089109A3
(en)
|
2015-05-22 |
2023-03-01 |
CSL Behring Lengnau AG |
Methods for preparing modified von willebrand factor
|
|
BR112017023785A2
(pt)
|
2015-05-22 |
2018-07-17 |
Csl Behring Recombinant Facility Ag |
polipeptídeos do fator de von willebrand truncados para tratar hemofilia
|
|
AU2016301303B2
(en)
|
2015-08-03 |
2021-10-07 |
Bioverativ Therapeutics Inc. |
Factor IX fusion proteins and methods of making and using same
|
|
DK3400238T3
(da)
|
2016-01-07 |
2021-07-26 |
CSL Behring Lengnau AG |
Muteret von willebrand faktor
|
|
RU2018128582A
(ru)
|
2016-01-07 |
2020-02-11 |
Цсл Беринг Ленгнау Аг |
Мутированный укороченный фактор фон виллебранда
|
|
EP3476860A4
(en)
*
|
2016-06-24 |
2020-01-22 |
Mogam Institute for Biomedical Research |
Recombinant single-chain fviii and chemical conjugate thereof
|
|
CN109475639A
(zh)
|
2016-07-22 |
2019-03-15 |
尼克塔治疗公司 |
具有含肟键联的因子viii部分的轭合物
|
|
SG11201903954WA
(en)
|
2016-11-11 |
2019-05-30 |
CSL Behring Lengnau AG |
Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
|
|
US11814421B2
(en)
|
2016-11-11 |
2023-11-14 |
CSL Behring Lengnau AG |
Truncated von Willebrand Factor polypeptides for treating hemophilia
|
|
CN110520149A
(zh)
|
2016-12-02 |
2019-11-29 |
比奥维拉迪维治疗股份有限公司 |
诱导对凝血因子的免疫耐受性的方法
|
|
WO2018102743A1
(en)
|
2016-12-02 |
2018-06-07 |
Bioverativ Therapeutics Inc. |
Methods of treating hemophilic arthropathy using chimeric clotting factors
|
|
JP7091373B2
(ja)
|
2017-06-22 |
2022-06-27 |
カタリスト・バイオサイエンシーズ・インコーポレイテッド |
改変された膜型セリンプロテアーゼ１（ｍｔｓｐ－１）ポリペプチドおよび使用方法
|
|
US11491212B1
(en)
|
2017-09-27 |
2022-11-08 |
Catalyst Biosciences, Inc. |
Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
|
|
US20190351031A1
(en)
|
2018-05-16 |
2019-11-21 |
Halozyme, Inc. |
Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
|
|
JP7763589B2
(ja)
|
2018-05-18 |
2025-11-04 |
バイオベラティブ セラピューティクス インコーポレイテッド |
血友病ａを処置する方法
|
|
PL3823904T3
(pl)
*
|
2018-07-20 |
2026-02-23 |
Hercules Llc |
Kompozycja rozpuszczalna lub dyspergowalna w wodzie
|
|
US11613744B2
(en)
|
2018-12-28 |
2023-03-28 |
Vertex Pharmaceuticals Incorporated |
Modified urokinase-type plasminogen activator polypeptides and methods of use
|
|
PE20211664A1
(es)
|
2018-12-28 |
2021-08-26 |
Catalyst Biosciences Inc |
Polipeptidos de activador de plasminogeno, tipo urocinasa, modificados y metodos de uso
|
|
WO2021154414A2
(en)
|
2020-01-29 |
2021-08-05 |
Catalyst Biosciences, Inc. |
Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides
|
|
US12232007B2
(en)
*
|
2021-06-03 |
2025-02-18 |
Apple Inc. |
Systems and methods for emergency service access by reduced capability radio frequency devices
|
|
WO2025227129A2
(en)
|
2024-04-25 |
2025-10-30 |
Starrock Pharma Llc |
Delivery vehicles comprising proglucagon derived polypeptides and anabolic polypeptides and uses thereof
|